A previous study showed that AREG and EREG expression can be modulated by fibroblast growth factor receptor 4 (FGFR4), an RTK known to promote proliferation, EMT, and decreased response to chemotherapy in CRC [81]. Here, EREG is linked to colorectal carcinoma.